Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Invivyd has a consensus analyst rating of “Hold” from six covering firms, with one sell, two hold, and three buy ratings. The average 12-month price target is $8.00.
• The company recently reported weaker-than-expected quarterly results, posting EPS of ($0.13) versus estimates of ($0.08) and revenue of $13.74 million versus expected $18.04 million.
• Invivyd’s stock was trading at $0.83, well below its 52-week high of $3.07, as the company continues to focus on antibody-based treatments and COVID-19 prevention candidates.

Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have received a consensus rating of "Hold" from the six research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $8.00.

Several research firms have recently commented on IVVD. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Invivyd in a research report on Wednesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Invivyd in a report on Monday, June 15th. Wall Street Zen lowered shares of Invivyd from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 16th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Invivyd in a report on Tuesday.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently modified their holdings of the business. Courier Capital LLC bought a new position in Invivyd in the 4th quarter worth $25,000. Bronte Capital Management Pty Ltd. bought a new stake in Invivyd during the fourth quarter valued at about $27,000. DRW Securities LLC purchased a new stake in Invivyd in the fourth quarter worth about $27,000. ProShare Advisors LLC purchased a new stake in Invivyd in the fourth quarter worth about $30,000. Finally, State of Wyoming purchased a new stake in Invivyd in the fourth quarter worth about $30,000. Institutional investors own 70.36% of the company's stock.

Invivyd Stock Performance

NASDAQ IVVD opened at $0.83 on Thursday. Invivyd has a one year low of $0.48 and a one year high of $3.07. The stock has a 50-day moving average of $1.08 and a 200 day moving average of $1.59. The company has a market capitalization of $244.53 million, a price-to-earnings ratio of -2.68 and a beta of 0.67.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The firm had revenue of $13.74 million during the quarter, compared to the consensus estimate of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. On average, equities analysts predict that Invivyd will post -0.5 earnings per share for the current fiscal year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.